Geode Capital Management LLC Has $712,000 Stock Position in Assembly Biosciences, Inc. (NASDAQ:ASMB)

Geode Capital Management LLC lowered its position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 13.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,034 shares of the biopharmaceutical company’s stock after selling 7,375 shares during the quarter. Geode Capital Management LLC owned about 0.74% of Assembly Biosciences worth $712,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC lifted its holdings in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares in the last quarter. Armistice Capital LLC acquired a new position in Assembly Biosciences in the second quarter valued at about $6,421,000. Renaissance Technologies LLC lifted its position in Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 15,451 shares during the period. Finally, Acadian Asset Management LLC lifted its position in Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 7,690 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.

Analysts Set New Price Targets

ASMB has been the subject of several recent analyst reports. Jefferies Financial Group raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $35.00 in a research report on Friday, September 20th. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Insider Transactions at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the acquisition, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.10% of the company’s stock.

Assembly Biosciences Price Performance

ASMB stock opened at $15.62 on Friday. Assembly Biosciences, Inc. has a 12 month low of $9.12 and a 12 month high of $19.93. The firm has a 50-day moving average price of $16.00 and a 200-day moving average price of $15.68.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.